Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.38 +7.6% TUNG 1.72 +1.8% LGO 1.01 −2.4% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.30 −2.0% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.73 −0.9% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.38 +7.6% TUNG 1.72 +1.8% LGO 1.01 −2.4% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.30 −2.0% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.73 −0.9%
Regulatory Admin

Canadian Investment Regulatory Organization Trading Halt - APTX

By The Northwire Desk — AI Analysis Jun 10, 2026 · 08:25 APTX NaN
APTX · Price

Executive Summary

  • The Canadian Investment Regulatory Organization (CIRO) has imposed a temporary trading halt on all issues of Apotex Health Corp. (TSX: APTX).
  • The halt is effective as of 8:00 AM ET on June 10, 2026.
  • The suspension is implemented to ensure a fair and orderly market, specifically citing an "If as and when issued opening" as the reason.

Key Details

  • Company: Apotex Health Corp.
  • TSX Symbol: APTX
  • Halt Reason: If as and when issued opening
  • Halt Time (ET): 8:00 AM
  • Issuing Authority: Canadian Investment Regulatory Organization (CIRO)
  • Scope: All issues of the company's securities are suspended from trading until further notice.
  • Purpose: Trading halts are implemented by CIRO to maintain fair and orderly market conditions.
Read the original news release →

More from NaN

Jul 01, 2026 · 09:00

Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex

M&A / Property Jul 01, 2026 · 01:47

Apotex Health receives Health Canada OK for Sevmia

Regulatory Jun 30, 2026 · 16:19

Apotex Capitalizes on GLP-1 Boom with First Canadian Generic Weight-Loss Approval Post-IPO

Regulatory Jun 16, 2026 · 08:58

Canadian pharma giant debuts on TSX with $1.5B capital raise, trading at a premium to IPO price

Financings Jun 11, 2026 · 11:18

Canadian pharma giant completes $1.3B IPO, debuts on TSX with a 12.5% pop.

Regulatory Jun 10, 2026 · 09:01

Record $1.3B life sciences IPO launches on TSX, valuing Canada's largest pharma at ~$5.6B.

Regulatory